Anixa Biosciences, Inc. is a clinical stage biotechnology company focused on the treatment and prevention of cancer.
Therapeutics
We are developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient’s own immune cells to fight cancer.
Vaccines
We are developing a revolutionary vaccine technology focused on treating and preventing multiple forms of breast cancer.
Using a similar mechanism of action as our breast cancer vaccine technology, we are developing a vaccine against ovarian cancer.
Lung, Colon, & Prostate Cancer Vaccines
We have commenced a cancer vaccine discovery program utilizing the same mechanism as our breast and ovarian cancer vaccines, to develop additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate.
Latest News & Events
Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial
Read More...Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Read More...Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Read More...